Audit 318522

FY End
2023-06-30
Total Expended
$34.61M
Findings
0
Programs
20
Year: 2023 Accepted: 2024-09-04
Auditor: Kpmg LLP

Organization Exclusion Status:

Checking exclusion status...

Contacts

Name Title Type
D529MMWMNHW3 Clinton Yee Auditee
8086911000 Amy Banovich Auditor
No contacts on file

Notes to SEFA

Title: (1) Basis of Presentation Accounting Policies: The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (QHS) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements. De Minimis Rate Used: N Rate Explanation: For the Research and Development Cluster, QHS did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as QHS has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2022. The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (the Company) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements.
Title: (2) Indirect Cost Rate Accounting Policies: The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (QHS) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements. De Minimis Rate Used: N Rate Explanation: For the Research and Development Cluster, QHS did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as QHS has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2022. For the Research and Development Cluster, the Company did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as the Company has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2023. For programs other than the Research and Development cluster, the Company elected to use the 10% de minimus indirect cost rate as discussed in the Uniform Guidance Section 200.414 if indirect costs are applicable to the grant.
Title: (3) Personal Protective Equipment Receipts (Unaudited) Accounting Policies: The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (QHS) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements. De Minimis Rate Used: N Rate Explanation: For the Research and Development Cluster, QHS did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as QHS has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2022. The Company did not receive any personal protective equipment in response to the COVID-19 pandemic for the year ended June 30, 2023.
Title: (4) Provider Relief Funds Accounting Policies: The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (QHS) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements. De Minimis Rate Used: N Rate Explanation: For the Research and Development Cluster, QHS did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as QHS has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2022. The Provider Relief Fund (PRF) program is administered by the Health and Human Resources and Services Administration to support eligible providers during the COVID-19 pandemic and was approved for funding originally under the Coronavirus Aid, Relief, and Economic Securities (CARES) Act. Funds were provided to eligible providers to support healthcare related expenses or lost revenues attributable to Coronavirus without application, but rather with terms and conditions. These terms and conditions required acceptance through an online portal or the funds would be returned. The Company accepted these conditions. The accompanying Schedule includes PRF for Period 4, defined as payments received between July 1, 2021 to December 31, 2021, and Period 5, for payments received between January 1, 2022 to June 30, 2022.